531739 Stock Overview Engages in manufacturing and selling of bulk drugs, intermediates, and biotech products. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Gennex Laboratories Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Gennex Laboratories Historical stock prices Current Share Price ₹16.33 52 Week High ₹29.00 52 Week Low ₹13.25 Beta 1.02 1 Month Change -13.18% 3 Month Change -24.99% 1 Year Change -4.84% 3 Year Change 48.19% 5 Year Change 509.33% Change since IPO 1,260.83%
Recent News & Updates
Gennex Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024 Nov 06
Gennex Laboratories Limited Announces Board Changes Oct 01
Investor sentiment deteriorates as stock falls 15% Oct 01
New minor risk - Share price stability Sep 26
Gennex Laboratories Limited, Annual General Meeting, Sep 30, 2024 Sep 13
Investor sentiment improves as stock rises 19% Sep 10 See more updates
Gennex Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024 Nov 06
Gennex Laboratories Limited Announces Board Changes Oct 01
Investor sentiment deteriorates as stock falls 15% Oct 01
New minor risk - Share price stability Sep 26
Gennex Laboratories Limited, Annual General Meeting, Sep 30, 2024 Sep 13
Investor sentiment improves as stock rises 19% Sep 10
Gennex Laboratories Limited Approves Appointment of Mohammed Khaleequr Rahman as Additional Director (Non- Executive-Non Independent) Sep 06
Investor sentiment improves as stock rises 18% Aug 22 Laxmipat Baid Tenders Resignation from the Post of Chief Financial Officer (Key Managerial Personnel) of Gennex Laboratories Limited Aug 15
Gennex Laboratories Limited to Report Q1, 2025 Results on Aug 14, 2024 Aug 05
Full year 2024 earnings released: EPS: ₹0.67 (vs ₹0.34 in FY 2023) Jun 04
Gennex Laboratories Limited to Report Q4, 2024 Results on May 30, 2024 May 23
Investor sentiment improves as stock rises 24% May 15
Investor sentiment improves as stock rises 20% Mar 20
New minor risk - Share price stability Mar 14
Investor sentiment deteriorates as stock falls 20% Mar 01
Third quarter 2024 earnings released: EPS: ₹0.16 (vs ₹0.067 in 3Q 2023) Feb 16
Gennex Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024 Feb 02
Gennex Laboratories Limited Announces Resignation of Tiruvarur Muralidharan Gopalakrishnan as Whole Time Director Feb 01 Gennex Laboratories Limited announced that it has received INR 794.695 million in funding from Premier Fiscal Services Pvt Ltd, Vidya Tradecon Pvt. Ltd., Vivaya Enterprises Private Limited, Jms Mines & Minerals Pvt Ltd Jan 29
New minor risk - Shareholder dilution Jan 28
Investor sentiment improves as stock rises 17% Jan 08
Insufficient new directors Jan 01 Gennex Laboratories Limited announced that it expects to receive INR 966.125 million in funding from Premier Fiscal Services Pvt Ltd Dec 04
Second quarter 2024 earnings released: EPS: ₹0.17 (vs ₹0.083 in 2Q 2023) Nov 20
Investor sentiment improves as stock rises 15% Nov 16
Gennex Laboratories Limited to Report Q2, 2024 Results on Nov 14, 2023 Nov 04
Investor sentiment deteriorates as stock falls 16% Oct 26
New major risk - Share price stability Oct 06
Investor sentiment improves as stock rises 19% Sep 28
Gennex Laboratories Limited, Annual General Meeting, Sep 30, 2023 Sep 07
First quarter 2024 earnings released: EPS: ₹0.16 (vs ₹0.06 in 1Q 2023) Aug 16
Gennex Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023 Aug 04
Investor sentiment improves as stock rises 25% Aug 03
New minor risk - Share price stability Aug 02
Full year 2023 earnings released: EPS: ₹0.32 (vs ₹0.31 in FY 2022) Jun 02
Investor sentiment improves as stock rises 15% Mar 03
Third quarter 2023 earnings released: EPS: ₹0.067 (vs ₹0.062 in 3Q 2022) Feb 15
Gennex Laboratories Limited Announces Rajesh Vankadara to Resign as Company Secretary & Compliance Officer Effect from February 26, 2023 Feb 08
Investor sentiment improved over the past week Dec 23
Second quarter 2023 earnings released: EPS: ₹0.083 (vs ₹0.09 in 2Q 2022) Nov 16
Now 20% undervalued after recent price drop Oct 03 Gennex Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023
Gennex Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022 Aug 02
Gennex Laboratories Limited Receives New 2 Licenses to Manufacture Drugs for Purposes of Examination, Test or Analysis from the Drug Control Administration , Government of Telangana Jul 28
Full year 2022 earnings released: EPS: ₹0.33 (vs ₹0.32 in FY 2021) Jun 04
Investor sentiment deteriorated over the past week May 11
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Feb 16
Investor sentiment improved over the past week Dec 29
Investor sentiment improved over the past week Dec 07
Investor sentiment improved over the past week Oct 12
Investor sentiment deteriorated over the past week Aug 20
First quarter 2022 earnings released: EPS ₹0.075 (vs ₹0.029 in 1Q 2021) Aug 18
Investor sentiment improved over the past week Jul 08
Investor sentiment improved over the past week Jun 23
Investor sentiment improved over the past week May 12
Investor sentiment improved over the past week Apr 25
Investor sentiment improved over the past week Apr 10
Investor sentiment deteriorated over the past week Mar 24
Third quarter 2021 earnings released: EPS ₹0.097 (vs ₹0.015 in 3Q 2020) Feb 15
Gennex Laboratories Limited to Report Q3, 2021 Results on Feb 13, 2021 Feb 04
Investor sentiment improved over the past week Feb 03
New 90-day high: ₹5.62 Jan 20
New 90-day high: ₹4.94 Jan 01 Gennex Laboratories Limited Appoints A S Nageswar Rao as Additional Director
Market bids up stock over the past week Dec 07
Market bids up stock over the past week Nov 25
Gennex Laboratories Limited Announces Resignation of Vinod Choraria as an Independent Director Nov 13
New 90-day low: ₹3.54 Nov 10
Gennex Laboratories Limited to Report Q2, 2021 Results on Nov 12, 2020 Nov 05
New 90-day low: ₹3.66 Oct 13
New 90-day low: ₹3.98 Sep 23
First quarter earnings released Sep 19
Full year earnings released - EPS ₹0.15 Sep 11
Gennex Laboratories Limited to Report Q1, 2021 Results on Sep 15, 2020 Sep 08
Full year earnings released - EPS ₹0.15 Aug 04
Gennex Laboratories Limited to Report Q4, 2020 Results on Jul 30, 2020 Jul 22 Shareholder Returns 531739 IN Pharmaceuticals IN Market 7D 1.9% 2.0% -0.3% 1Y -4.8% 39.5% 16.3%
See full shareholder returns
Return vs Market: 531739 underperformed the Indian Market which returned 16.3% over the past year.
Price Volatility Is 531739's price volatile compared to industry and market? 531739 volatility 531739 Average Weekly Movement 6.4% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 531739 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 531739's weekly volatility (6%) has been stable over the past year.
About the Company Gennex Laboratories Limited engages in manufacturing and selling of bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, Methocarbamol, Fexifenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl, and Allopurinol. It operates in India, Colombia, Egypt, Germany, Iran, Peru, Saudi Arabia, Spain, Thailand, and Vietnam.
Show more Gennex Laboratories Limited Fundamentals Summary How do Gennex Laboratories's earnings and revenue compare to its market cap? 531739 fundamental statistics Market cap ₹3.76b Earnings (TTM ) ₹172.90m Revenue (TTM ) ₹1.13b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 531739 income statement (TTM ) Revenue ₹1.13b Cost of Revenue ₹741.79m Gross Profit ₹383.39m Other Expenses ₹210.49m Earnings ₹172.90m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.76 Gross Margin 34.07% Net Profit Margin 15.37% Debt/Equity Ratio 15.7%
How did 531739 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/31 12:12 End of Day Share Price 2024/12/31 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Gennex Laboratories Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
